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The Crux of
Maximum Hyperemia
The Last Remaining Barrier for
Routine Use of Fractional Flow Reserve*
Nico H. J. Pijls, MD, PHD,
Pim A. L. Tonino, MD, PHD
Eindhoven, the Netherlands
In the decision-making process of revascularization of
coronary artery stenoses by percutaneous coronary interven-
tion (PCI) or coronary artery bypass graft surgery (CABG),
the presence and extent of reversible ischemia associated
with such particular stenoses is of paramount importance
(1–3). A stenosis associated with reversible ischemia (also
called functionally significant or hemodynamically signifi-
cant stenosis) causes symptoms of angina pectoris and has a
negative influence on outcome (1,2). Therefore, the general
feeling is that such lesions should be revascularized if
technically feasible. On the contrary, functionally nonsig-
nificant stenoses do not cause symptoms by definition and
have an excellent outcome with medical therapy (3–5).
Therefore, revascularization of such lesions is generally not
indicated.
See pages 1079 and 1085
In the ideal case, reversible ischemia should be docu-
mented before PCI or bypass surgery in a noninvasive way.
However, in most patients, such documentation is not
present, insufficient, or unreliable. The most important
reason for the lack of such data is that all known noninvasive
tests have a limited accuracy. Especially in the presence of
multivessel coronary artery disease, noninvasive tests are
rarely accurate enough to assess separately the ischemic
potential of an individual stenosis (6).
Fractional flow reserve (FFR), on the contrary, is a
stenosis-specific measure of ischemia and is considered as
the gold standard method to investigate whether any par-
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guided PCI has been shown to result in favorable outcomes
compared with angiography-guided PCI (3,4). Conse-
quently, in Europe, FFR currently enjoys class IA recom-
mendation for assessment of stable coronary stenosis ahead
of revascularization when other functional information is
lacking (7).
The technique of FFR measurement became available in
the catheterization laboratory in the late nineties but a
number of technical and practical shortcomings had to be
overcome before the technique could be applied as a routine
treatment in the catheterization laboratory (8–10).
Presently, the last remaining barrier of generalizing FFR
as a first-line catheterization laboratory tool is the issue of
achieving maximum coronary and myocardial hyperemia (11).
The principal of FFR is based upon the presence of true
maximum hyperemia. That is paramount. If full maximum
hyperemia is not present, FFR is overestimated and stenosis
severity underestimated (8–11).
At this point, the studies by Nair et al. (12) and by De
Luca et al. (13), published in this issue of JACC: Cardio-
vascular Interventions, come into perspective.
Presently, central intravenous administration of adeno-
sine at a rate of 140 g/kg/min is the gold standard of
aximum coronary hyperemia (11,14). Not only does this
reate a reproducible and maximum arteriolar vasodilata-
ion, but it also enables a hyperemic state lasting long
nough to make a reliable pullback recording along a
iseased artery. If adenosine is not administered by a central
enous line but by peripheral infusion, sometimes its action
ay be less reliable because adenosine is rapidly inactivated
n blood, and a maximum hyperemic status is not always
chieved. Some operators have increased this peripheral
enous dosage to 180 g/kg/min, others were prone to
ncrease the ischemic threshold of FFR in such a case, but
e should admit such actions mean covering one mistake by
nother.
Despite the fact that central venous infusion of adenosine
s the gold standard, and insertion of a femoral sheath is very
asy in a catheterization laboratory, it does entail a small
dditional risk and, in the case of radial procedures, is
nconvenient.
The alternative is intracoronary administration of aden-
sine, which does not require central venous canulation but
nly creates very short-lasting hyperemia that is insufficient
o make a pressure pullback recording (11,14). In patients
ith a single stenosis in an otherwise rather normal coronary
rtery, that is not a true problem. But unfortunately, most of
ur patients have multivessel disease, multiple abnormalities
long a coronary artery, or focal lesions superimposed upon
iffused disease. Therefore, when using intracoronary aden-
sine, only the total FFR is obtained, without information
bout the pressure decline along the coronary artery. So,
art of the essential information is lacking, and it is difficult
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1094to judge whether it makes sense to stent (in case of focal
pressure drops) or not (in case of a gradual decline of
pressure) (15).
Furthermore, reliable intracoronary administration of
adenosine requires a stable guiding catheter position to
avoid spillage into the aorta. However, a guiding catheter
too deeply engaged might partly prevent true maximum
hyperemia. This makes intracoronary adenosine a much
more complicated hyperemic stimulus than often believed,
producing ambiguity with respect to the necessary dosage
(as shown by De Luca et al. [13]), along with difficulties in
interpretation, and is often much more time-consuming
compared with centrally administered intravenous adenosine.
Furthermore, the use of intracoronary adenosine is com-
plicated by the very short half-life without a steady-state. In
the study by De Luca et al. (13), the good news is that the
absolute differences in FFR between the lowest and highest
doses of adenosine were very small (decreasing from 0.79 to
0.77) and most likely none, or very few, of their patients
moved from above the currently accepted upper limit of the
gray zone of FFR (0.76 to 0.80) to below the lower limit.
Intracoronary papaverine, in a dosage of 8 to 12 mg in the
right coronary artery and 12 to 20 mg in the left coronary
artery, is an alternative method creating sufficiently long
hyperemia (30 to 60 s) to make a pullback recording, with
some dislodging of the guiding catheter if indicated, but is
less used in the United States and Western Europe because
of a small risk of polymorphous ventricular tachycardia
(11,14).
The ideal hyperemic stimulus should be easy to admin-
ister (e.g., in a peripheral venous infusion or intracoro-
narily), have a short onset until maximum hyperemia is
achieved, have a duration long enough to enable pressure
pullback recordings (a few minutes), have few side effects,
and be eliminated within a few minutes.
In the paper by Nair et al. (12), such a stimulus is
proposed, i.e., regadenoson in a dosage of 400 g as a single
injection in a peripheral infusion. If a central vein is present,
it might be assumed that it will act in a similar way. The
study by Nair et al. (12) was carefully performed and
encouraging because the rate of hyperemia was almost
exactly identical to intravenous adenosine without misclas-
sifying any stenosis when the FFR threshold of 0.80 was
used (16). The hemodynamic effects (a slight decrease in
blood pressure and increase in heart rate) were comparable
between both stimuli, whereas only minimal subjective side
effects were observed.
However, before accepting regadenoson as a sufficient
(and maybe ideal) hyperemic stimulus for FFR measure-
ment, some more work has to be done, and a number of
limitations should be critically assessed. First, the study by
Nair et al. (12) was performed in a small group of patients
with intermediate stenoses in single-vessel disease only and
under favorable clinical conditions. In those patients, amarvelous correlation was found between both intravenous
adenosine as a gold standard and regadenoson as the
proposed alternative. Furthermore, the assessment of side
effects was somewhat clouded by the fact that the patients in
this study were sedated, which is not routine in patients
undergoing PCI in a catheterization laboratory. Validation
in many more patients over a larger range of stenoses and a
larger variety of clinical conditions should be performed.
Furthermore, in creating maximum hyperemia in a cor-
onary artery for FFR measurement, 2 aspects are important:
induction of truly maximum hyperemia to calculate FFR
and maintaining maximum hyperemia for a period long
enough to perform a pressure pullback recording to analyze
a decline of pressure along the artery. From the data by Nair
et al. (12), it seems that regadenoson is sufficient, but in
their study, no exact time intervals were measured with
respect to the duration of action of regadenoson.
In addition, the measurements were not performed in
duplicate, and before accepting regadenoson as the gold
standard, reproducibility should be tested.
Next, measurements and validation versus intravenous
adenosine should also be performed over a wider spectrum
of stenosis severity with FFR values over the complete range
(in stable patients between 0.35 and 1.00).
The study by Nair et al. (12) was performed meticulously,
using state-of-the-art FFR measurements. The authors
equalized pressures before entering the coronary artery,
careful attention was paid to avoid arterial pressure damping
(1 of the reasons why FFR can be measured artificially too
high), and the pressure differences were assessed on a
beat-to-beat basis and not from a mean pressure tracing
which can lead to overestimation of FFR, especially when
intracoronary adenosine is used.
Also and importantly, the authors took the responsibility
and consequences of their actions by strictly adhering to
treating patients with FFR 0.80 and deferring PCI or
CABG in patients with FFR 0.80.
As mentioned, the side effects of both drugs seemed to be
favorable although this group of patients is very small. The
authors are careful to say that regadenoson maybe safely
used with mild or moderate reactive airway disease and
chronic obstructive pulmonary disease. It should be empha-
sized that adenosine is also safe in these patients and that
only in cases of severe asthma, might intravenous adenosine
cause problems.
In the practice of the authors of this editorial in more
than 10,000 patients in whom intravenous adenosine was
administered for FFR measurement, severe asthma attacks
were only observed 3 times. More often, the subjective and
harmless feeling of dyspnea experienced by patients receiv-
ing adenosine-like drugs (also regadenoson) is sometimes
confused with asthma. Safety of intravenous adenosine is
beyond doubt, and it might be anticipated that the same
holds true for regadenoson.
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1095Obtaining a reliable FFR measurement depends on
induction of maximum coronary hyperemia. Failure to
induce maximum hyperemia will result in overestimation of
FFR and undertreatment of the patient. Therefore, the
endeavors to find easier hyperemic stimuli are important
and the authors of the papers in this issue of JACC:
Cardiovascular Interventions, should be commended for
their contribution.
Nevertheless, further studies in a larger group of patients
with a large variety of stenosis severity and clinical conditions,
and further investigation of the time intervals of action, are
mandatory before large-scale use of regadenoson for FFR
measurement can be recommended. In the mean time, it is
likely that operators experienced in fractional flow reserve, will
already build up experience on a compassionate-use basis.
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